Blog
Blog
Why Enterprise AI Feels Like a Disappointment for Life Sciences Teams
You have used tools like ChatGPT. They are fast, helpful, almost fun. Then your company deploys its own AI platform and something feels off. It hedges. It refuses. It does not understand your business, markets, or data. You are not imagining the gap.
Filter posts by:
Blog
The Future of Cell Therapy: What’s Next?
Executive Summary Trinity’s Take: New cell therapy technologies show blockbuster potential for improved accessibility and efficacy in a wide range of indications, though these therapies come with their own downfalls that healthcare systems will need to adapt to in order for...
Blog
ICER Released First Cost-Effectiveness Assessment for a Digital Therapeutic (DTx)
Three digital health technologies have been developed to treat opioid use disorder (OUD). These applications, reSET-O (Pear Therapeutics), Connections (Chess Health) and DynamiCare (DynamiCare Health) [...]
Blog
FDA Launches the Digital Health Center of Excellence
Written by Tom Rutkowski, Jay Galli, and Kate Watkins
Blog
CAR-Ts: Barriers and Opportunities for the Migration into Earlier Lines of Therapy in the USA
Although CAR Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment. Key barriers for CAR T migration into earlier lines include the complex logistics and site...
Blog
Ten Long-Term Impacts of COVID-19 on Biopharma
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski
Blog
Access and Reimbursement: Access to Digital Therapeutics in a Post-COVID-19 World
Digital therapeutics (DTx) represent a novel approach to delivering improved clinical outcomes, but the unstructured nature of today’s DTx access process has presented a major hurdle to broader uptake.
Payers are still at very different stages in their acceptance of DTx, and...
